Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OptiNose, Inc.    OPTN

OPTINOSE, INC.

(OPTN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
4.09(c) 4.11(c) 4.45(c) 4.29(c) 4.06(c) Last
668 391 537 049 873 880 389 859 487 917 Volume
+0.74% +0.49% +8.27% -3.60% -5.36% Change
More quotes
Financials (USD)
Sales 2020 50,8 M - -
Net income 2020 -98,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,96x
Yield 2020 -
Sales 2021 104 M - -
Net income 2021 -64,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,17x
Yield 2021 -
Capitalization 211 M 211 M -
Capi. / Sales 2020 4,17x
Capi. / Sales 2021 2,03x
Nbr of Employees 223
Free-Float 59,3%
More Financials
Company
OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath... 
Sector
Pharmaceuticals
Calendar
03/11Earnings Release
More about the company
Notations Surperformance© of OptiNose, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about OPTINOSE, INC.
01/26OPTINOSE : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
01/25OPTINOSE : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
2020INSIDER TRENDS : Optinose Insider Converts/Exercises Derivative Security, Sells ..
MT
2020OPTINOSE : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
2020Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2020INSIDER TRENDS : Insider at Optinose Converts/Exercises Derivative Security, Sel..
MT
2020OPTINOSE, INC. : Creation of a Direct Financial Obligation or an Obligation unde..
AQ
2020OPTINOSE, INC. : Change in Directors or Principal Officers, Regulation FD Disclo..
AQ
2020Optinose Announces Changes to Board of Directors
GL
2020INSIDER TRENDS : Optinose Insider Converts/Exercises Derivative Security, Sells ..
MT
2020INSIDER TRENDS : Insider at Optinose Converts/Exercises Derivative Security, Sel..
MT
2020OPTINOSE, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2020OPTINOSE : 3Q Earnings Snapshot
AQ
2020OPTINOSE : Corporate Presentation
PU
2020Earnings Flash (OPTN) OPTINOSE Posts Q3 Revenue $15.4M, vs. Street Est of $15..
MT
More news
News in other languages on OPTINOSE, INC.

- No features available -

More news
Chart OPTINOSE, INC.
Duration : Period :
OptiNose, Inc. Technical Analysis Chart | OPTN | US68404V1008 | MarketScreener
Technical analysis trends OPTINOSE, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 17,00 $
Last Close Price 4,06 $
Spread / Highest target 393%
Spread / Average Target 319%
Spread / Lowest Target 220%
EPS Revisions
Managers and Directors
NameTitle
Peter Kaighn Miller Chief Executive Officer & Director
Ramy A. Mahmoud President & Chief Operating Officer
Joseph C. Scodari Independent Chairman
Keith Alan Goldan Chief Financial Officer
John C. Messina SVP-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
OPTINOSE, INC.-1.93%211
JOHNSON & JOHNSON6.67%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.-1.55%207 384
MERCK & CO., INC.-1.89%203 035